Among the 6 immune checkpoints, CTLA4, CD86, and PDCD1LG2 were highly expressed in the high-risk group (Wilcoxon rank-sum test, p < 0.05; Figure 6B), suggesting that these genes may serve as key targets for anti-tumor therapy in CRC. This evidence concerns the gene CD86 and colorectal carcinoma.